Claims

1. Use of
(a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and
(b) a chemotherapeutic agent, wherein the chemotherapeutic agent is a topoisomerase inhibitor or a thymidylate synthase inhibitor
in the preparation of a medicament for the treatment of a cancer, wherein the cancer is a cancer associated with a p53 mutation.

2. The use according to claim 1 wherein the cancer is one or more of colorectal, breast, ovarian, cervical, gastric, lung, liver, skin and myeloid (e.g. bone marrow) cancer.

3. The use according to claim 1 or claim 2 wherein the death receptor is FAS.

4. The use according to claim 1 or claim 2 wherein the binding member is an antibody or a fragment thereof.

5. The use according to any one of the preceding claims wherein the binding member is the anti-FAS antibody CH11.

6. The use according to any one of the preceding claims wherein said chemotherapeutic agent is an antifolate thymidylate synthase inhibitor or

a topoisomerase-I inhibitor.

7. The use according to any one of the preceding claims, wherein said chemotherapeutic agent is TDX or irinotecan (CPT-11).

8. The use according to any one of the preceding claims, wherein said specific binding member and chemotherapeutic agent are provided in concentrations sufficient to produce an RI of greater than 1.5.

9. A method of killing cancer cells having a p53 mutation, said method comprising the separate, sequential or simultaneous administration to said cells of a therapeutically effective amount of a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent, wherein said chemotherapeutic agent is a topoisomerase inhibitor or a thymidylate synthase inhibitor.

10. A method of treating cancer cells having a p53 mutation comprising the separate, sequential or simultaneous administration to a mammal in need thereof of a therapeutically effective amount of a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent, wherein said chemotherapeutic agent is a topoisomerase

inhibitor or a thymidylate synthase inhibitor.

11. The method according to claim 9 or claim 10 wherein the cancer is one or more of colorectal, breast , ovarian, cervical, gastric, lung, liver, skin and myeloid (e.g. bone marrow) cancer.

12. The method according to claim 9, 10 or 11 wherein the binding member is an antibody or a fragment thereof.

13. The method according to any one of claims 9 to 12 wherein the death receptor is FAS.

14. The method according to any one of claims 9 to 13 wherein the binding member is the anti-FAS antibody CH11.

15. The method according to any one of claims 9 to 14 wherein said chemotherapeutic agent is an antifolate thymidylate synthase inhibitor or a topoisomerase-I inhibitor.

16. The method according to any one of claims 9 to 15 wherein, wherein said chemotherapeutic agent is TDX or irinotecan (CPT-11).

17. The method according to claim 16 wherein said specific binding member and chemotherapeutic agent are provided in concentrations sufficient

to produce an RI of greater than 1.5.

18. A product comprising a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent as a combined preparation for the simultaneous, separate or sequential use in the treatment of cancer, wherein said chemotherapeutic agent is a topoisomerase inhibitor or a thymidylate synthase inhibitor, and wherein the cancer cells comprise a p53 mutation.

19. A pharmaceutical composition characterised by the presence of a p53 mutation, wherein the composition comprises a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent, wherein said chemotherapeutic agent is a topoisomerase inhibitor or a thymidylate synthase inhibitor and (c) a pharmaceutically acceptable excipient, diluent or carrier..

20. The product according to claim 18 or the pharmaceutical composition according to claim 19 wherein the cancer is one or more of colorectal, breast , ovarian, cervical, gastric, lung, liver, skin and myeloid (e.g. bone marrow) cancer.

21. The product according to claim 18 or claim 20 or the pharmaceutical composition according to claim 19 or claim 20 wherein the binding member is an antibody or a fragment thereof.

22. The product according to claim 18 or claim 20 or 21 or the pharmaceutical composition according to claim 19 or claim 20 or 21 wherein the death receptor is FAS.

23. The product according to claim 18 or any one of claims 20 to 22 or the pharmaceutical composition according to claim 19 or or any one of claims 20 to 22 wherein the binding member is the anti-FAS antibody CH11.

24. The product according to claim 18 or any one of claims 20 to 23 or the pharmaceutical composition according to claim 19 or or any one of claims 20 to 23 wherein said chemotherapeutic agent is an antifolate thymidylate synthase inhibitor or a topoisomerase-I inhibitor.

25. The product according to claim 18 or any one of claims 20 to 24 or the pharmaceutical composition according to claim 19 or or any one of claims 20 to 24, wherein said chemotherapeutic agent is TDX or irinotecan (CPT-11).

26. The product or pharmaceutical composition according to claim 25 wherein said specific binding member and chemotherapeutic agent are provided in concentrations sufficient to produce an RI of greater than 1.5.

27. A kit for the treatment of a cancer characterised by the presence of a p53 mutation, said kit comprising a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent, wherein said chemotherapeutic agent is a topoisomerase inhibitor or a thymidylate synthase inhibitor and (c) instructions for the administration of (a) and (b) separately, sequentially or simultaneously.